Key facts
- This page summarizes Alexander J. Denner's Form 4 filing for IRONWOOD PHARMACEUTICALS INC (IRWD).
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 17 Mar 2026, 20:34.
Alexander J. Denner - 13 Mar 2026 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)
- Reporting relationship
- Director
- Issuer ticker
- IRWD
- Reported as of
- 13 Mar 2026
- Net transaction value
- -$20,530,448
- SEC form
- 4
- Accepted by SEC
- 17 Mar 2026, 20:34:48 UTC
- Prior SEC filing
- 17 Dec 2025
- Next SEC filing
- 17 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alexander Denner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alexander J. Denner filed Form 4 for IRONWOOD PHARMACEUTICALS INC (IRWD) on 17 Mar 2026.
Change
- Previous filing in this sequence was filed on 17 Dec 2025.
- Current net transaction value: -$20,530,448.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001361754
Primary reporting owner
DENNER ALEXANDER J
- Relationship
- Director
- Address
- C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON
- Signature
- /s/ Alexander Denner
- Signature date
- 17 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IRWD
transaction
Class A Common Stock
Award
- Transaction value
- Shares
- +4,451
- Change %
- +1.8%
- Price
- $0.000000*
- Shares after
- 256,309
- Date
- 13 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
IRWD
transaction
Class A Common Stock
Sale
- Transaction value
- $20,511,250
- Shares
- -6,725,000
- Change %
- -42%
- Price
- $3.05
- Shares after
- 9,194,435
- Date
- 17 Mar 2026
- Ownership
- See footnote
- Footnotes
- F2
IRWD
transaction
Class A Common Stock
Sale
- Transaction value
- $19,198
- Shares
- -5,800
- Change %
- -0.06%
- Price
- $3.31
- Shares after
- 9,188,635
- Date
- 17 Mar 2026
- Ownership
- See footnote
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Issued pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
Footnote F2
Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of SarissaCapital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein.
SEC remarks
Exhibit 24 - Power of Attorney